MJFF Partners with Imago Pharmaceuticals to Study Parkin Protein

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has acquired research tools from Imago Pharmaceuticals (originally developed by Elan Pharmaceuticals) to accelerate research and drug development surrounding the therapeutic target parkin. Mutations in the parkin (PARK2) gene lead to early onset Parkinson’s disease (PD) caused by dysfunction of the parkin protein, a component of the E3 ubiquitin ligase complex. Although it is most well known for its role in PD, it is also linked to ALS through the mitophagy pathway and optineurin (see Oct 2014 news story) and though its effect on TDP-43 (see Jan 2013 news story). The newly acquired research tools include cell lines, plasmids and compounds, which will initially be integrated into MJFF-funded studies, but will be available to the broader research community later this year.

Click here to read more.

disease-pd topic-preclinical
Share this: